Type of MS: RRMS
Treatment mode of action: To affect immune function
Number of Subjects: 1050
Medication: IMU-838 (vidofludimus calcium), a small molecule inhibitor of dihydroorotate dehydrogenase
Location: Massachusetts
Institutions: Boston Clinical Trials
26 Cummins Hwy, Boston, MA 02131
Contact Information
Joanne Monaghan
617-685-7530
studies@bostontrials.com